Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan;18(1 Suppl):S46-52.
doi: 10.1016/j.bbmt.2011.10.021.

Fibrotic and sclerotic manifestations of chronic graft-versus-host disease

Carrie L Kitko  1 , Eric S White, Kristin Baird
Affiliations
Review

Fibrotic and sclerotic manifestations of chronic graft-versus-host disease

Carrie L Kitko et al. Biol Blood Marrow Transplant. 2012 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of etanercept on survival in post-HCT patients with subacute lung injury. A) Overall 5-year survival by pulmonary function testing defect. Patients with an obstructive defect (solid line) had a 5-year survival of 67% compared to 44% in those with a restrictive lung defect (dashed line) (p=0.19). B) Overall 5-year survival by response to therapy. Patients who responded to etanercept therapy (solid line) had a 5-year survival of 90% compared to 55% in patients who failed to respond (dashed line) (p=0.07). (Figures re-printed with permission, Biol Blood and Marrow Trans).
See this image and copyright information in PMC

References

    1. Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138:924–934. - PubMed
    1. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106–114. - PMC - PubMed
    1. Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis. 2010;69(Suppl 1):i48–51. - PubMed
    1. Tarrats N, Moles A, Morales A, Garcia-Ruiz C, Fernandez-Checa JC, Mari M. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology. 2011;54:319–327. - PMC - PubMed
    1. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90:812–823. - PMC - PubMed

MeSH terms